| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
License revenue | ||||||
40,560 | - | - | ||||
Operating expenses: | ||||||
Cost of license revenue | ||||||
2,500 | - | - | ||||
Research and development | ||||||
209,947 | 140,073 | 30,556 | ||||
General and administrative | ||||||
94,353 | 43,587 | 13,302 | ||||
Total operating expenses | ||||||
306,800 | 183,660 | 43,858 | ||||
Loss from operations | ||||||
-266,240 | -183,660 | -43,858 | ||||
Other income (expense), net: | ||||||
Interest income | ||||||
8,915 | 2,004 | 39 | ||||
Interest expense | ||||||
8,765 | 2,547 | 13 | ||||
Gain on deconsolidation of PellePharm | ||||||
- | 19,327 | - | ||||
Loss from ML Bio asset acquisition | ||||||
416 | - | - | ||||
Share in net loss of an equity method investment | ||||||
-20,869 | -275 | - | ||||
Other expense | ||||||
1,210 | 4,300 | - | ||||
Total other income (expense), net | ||||||
-22,345 | 14,209 | 26 | ||||
Net loss | ||||||
-288,585 | -169,451 | -43,832 | ||||
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | ||||||
-27,998 | -38,702 | -13,267 | ||||
Net loss attributable to common stockholders of BridgeBio | ||||||
-260,587 | -130,749 | -30,565 | ||||
Net loss per share, basic and diluted | ||||||
-2.48 | -2.12 | -1.00 | ||||
Weighted-average shares used in computing net loss per share, basic and diluted | ||||||
105,099 | 61,767 | 30,598 | ||||